Angela Boutte
Dr. Boutte Joins PRECISE-TBI Biomarker Working Group
Aries Biotech extends gratitude to the PRECISE-TBI team, for inviting Dr. Angela Boutte, the founder of Aries Biotech, to participate in the preclinical common data elements working group. Led by Dr. Michelle LaPlaca of Georgia Tech and Emory University, Dr. Neil Harris of UCLA, and an esteemed group of internationally known brain trauma experts, PRECISE-TBI seeks to develop a catalogue of terms to benefit harmonization of preclinical brain trauma models and biomarker data. Aries Biotech supports data sharing, rigor, and reproducibility through collaboration and alignment with the National Institutes of Health (NIH) Data Management and Sharing Policy (DMSP).
Additional information about PRECISE-TBI may be found at
Aries Biotech is a neurological disease and dementia biomarker consulting company that provides guidance, data interpretation, document review, and investor support. To learn more, visit Aries Biotech at https://www.ariesbiotechnologies.com .
Check out our community interest survey at https://forms.wix.com/f/7075978737291886849
#neuroscience #neurology #neurologicaldisease #TBI #biomarker #diagnostics #IVD #translationalmodel #therapeutics #data